SCHEMBL6410260

SCHEMBL6410260

COc1ccc(N2CCN(c3ccccc3)C2=O)cc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 7/20 0.57
HTR2B P41595 5/20 0.57
HTR2A P28223 5/20 0.57
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 2/20 0.52
MCHR1 Q99705 1/20 0.44
CTSG P08311 1/20 0.44
CMA1 P23946 1/20 0.44
PDE4A P27815 1/20 0.44
PDE4B Q07343 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
GAA P10253 1/20 0.44
TUBB1 Q9H4B7 1/20 0.43
PSMB1 P20618 1/20 0.43
PSMB5 P28074 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6408330 0.87 HTR2C (0.68) HTR2CHTR2BHTR2AMEN1KMT2A
SCHEMBL6415386 0.84 HTR2C (0.61) HTR2CHTR2BHTR2AMEN1KMT2A
SCHEMBL6414633 0.78 HTR2C (0.62) HTR2CHTR2BHTR2AMEN1KMT2A
SCHEMBL2325995 0.78 HTR2C (0.55) HTR2CHTR2BHTR2AMEN1KMT2A
SCHEMBL11115287 0.75 MAPT (0.58) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL6140654 0.74 HTR2C (0.54) HTR2CHTR2BHTR2AMEN1KMT2A
SCHEMBL610584 0.74 NPC1 (1.00) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL6409575 0.73 HTR2C (1.00) HTR2CHTR2BHTR2A
SCHEMBL6109613 0.73 HTR2C (0.47) HTR2CHTR2BHTR2AMEN1KMT2A
SCHEMBL22502096 0.72 KMT2A (0.43) MEN1KMT2ANPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154028-A1 Cyclic urea derivatives with 5-ht2c receptor activity GLAXO GROUP LIMITED (GB) 2005-07-14 US disclosed
EP-1465630-A1 CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY GLAXO GROUP LIMITED (GB) 2004-10-13 EP disclosed
WO-2003057220-A1 CYCLIC UREA DERIVATIVES WITH 5-HT2C RECEPTOR ACTIVITY GLAXO GROUP LIMITED (GB) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154028-A1 Cyclic urea derivatives with 5-ht2c receptor activity HTR2C, HTR3C, HTR5A HTR2C 1/4885HTR2B 28/4885HTR2A 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.